Dawn of CAR-T cell therapy in autoimmune diseases

Abstract Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies. Based on the immunomodulatory capability of CAR-T cells, efforts have turned toward exploring their potential in treating autoimmune diseases. Bibliometric analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases, covering a range of subtypes such as systemic lupus erythematosus, multiple sclerosis, among others. CAR-T therapy holds promise in mitigating several shortcomings, including the indiscriminate suppression of the immune system by traditional immunosuppressants, and non-sustaining therapeutic levels of monoclonal antibodies due to inherent pharmacokinetic constraints. By persisting and proliferating in vivo, CAR-T cells can offer a tailored and precise therapeutics. This paper reviewed preclinical experiments and clinical trials involving CAR-T and CAR-related therapies in various autoimmune diseases, incorporating innovations well-studied in the field of hematological tumors, aiming to explore a safe and effective therapeutic option for relapsed/refractory autoimmune diseases.

[1]  A. Schreiber,et al.  CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury , 2024, Annals of the Rheumatic Diseases.

[2]  A. Künkele,et al.  Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells , 2023, Cell.

[3]  Wei Li,et al.  Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments , 2023, Chinese medical journal.

[4]  A. Mackensen,et al.  Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies , 2023, Rheumatology.

[5]  M. Benatar,et al.  Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study , 2023, The Lancet Neurology.

[6]  C. Lengerke,et al.  CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome. , 2023, JAMA.

[7]  M. Hust,et al.  Generation of Chimeric Antigen Receptors against Tetraspanin 7 , 2023, Cells.

[8]  A. Mackensen,et al.  CD19-targeted CAR T cells in refractory antisynthetase syndrome , 2023, The Lancet.

[9]  Gregory F. Wu,et al.  CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity , 2023, Neurology: Neuroimmunology & Neuroinflammation.

[10]  D. Richman,et al.  Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells , 2023, Nature Biotechnology.

[11]  A. Liang,et al.  Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature , 2023, Frontiers in Immunology.

[12]  W. Wang,et al.  Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results , 2023, Journal of the Neurological Sciences.

[13]  R. Brentjens,et al.  GPRC5D-Targeted CAR T Cells for Myeloma. Reply. , 2022, New England Journal of Medicine.

[14]  M. Levings,et al.  Flagellin-specific human CAR Tregs for immune regulation in IBD. , 2022, Journal of autoimmunity.

[15]  S. Riddell,et al.  Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours , 2022, Nature reviews. Clinical oncology.

[16]  S. Jagannath,et al.  Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy. , 2022, Blood.

[17]  C. June,et al.  CAR T therapy extends its reach to autoimmune diseases , 2022, Cell.

[18]  A. Nierhaus,et al.  Cytokine Storm—Definition, Causes, and Implications , 2022, International journal of molecular sciences.

[19]  A. Ekici,et al.  Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus , 2022, Nature Medicine.

[20]  Qian Wang,et al.  Chinese registry of rheumatoid arthritis (CREDIT) V: sex impacts rheumatoid arthritis in Chinese patients , 2022, Chinese medical journal.

[21]  Ming-Yu Liu,et al.  Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL , 2022, Nature.

[22]  D. Mougiakakos,et al.  OP0279 CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS , 2022, Annals of the Rheumatic Diseases.

[23]  Huizhong Li,et al.  Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  He Huang,et al.  Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL , 2022, Blood.

[25]  L. Sehn,et al.  CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift? , 2022, Blood.

[26]  Allison M. Keeler,et al.  CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications , 2022, Biomedicines.

[27]  Yu-jing Li,et al.  Cell-based therapies for rheumatoid arthritis: opportunities and challenges , 2022, Therapeutic advances in musculoskeletal disease.

[28]  M. Radic,et al.  CD8+ T Cells Expressing an HLA-DR1 Chimeric Antigen Receptor Target Autoimmune CD4+ T Cells in an Antigen-Specific Manner and Inhibit the Development of Autoimmune Arthritis , 2021, The Journal of Immunology.

[29]  B. Weinshenker,et al.  Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials , 2021, Nature Reviews Neurology.

[30]  M. Etemadifar,et al.  Inducing chimeric antigen receptor (CAR) regulatory T cells in-vivo: A novel concept for a potential feasible cure of demyelinating diseases. , 2021, Multiple sclerosis and related disorders.

[31]  S. Luo,et al.  Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases. , 2021, Autoimmunity reviews.

[32]  Lei Xu,et al.  Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR , 2021, Stem Cell Reviews and Reports.

[33]  A. Mackensen,et al.  CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. , 2021, The New England journal of medicine.

[34]  S. Jagannath,et al.  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.

[35]  S. Steinberg,et al.  Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Busch,et al.  Formation and immunomodulatory function of meningeal B-cell aggregates in progressive CNS autoimmunity. , 2021, Brain : a journal of neurology.

[37]  Li Yang,et al.  CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia , 2021, Clinical Cancer Research.

[38]  M. Maus,et al.  Recent advances and discoveries in the mechanisms and functions of CAR T cells , 2021, Nature Reviews Cancer.

[39]  K. Kridin,et al.  Milestones in Personalized Medicine in Pemphigus and Pemphigoid , 2021, Frontiers in Immunology.

[40]  J. Makowska,et al.  Antisynthetase syndrome - much more than just a myopathy. , 2020, Seminars in arthritis and rheumatism.

[41]  A. Rapoport,et al.  Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy. , 2020, Blood advances.

[42]  J. Gauthier,et al.  Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL , 2020, Bone Marrow Transplantation.

[43]  X. Montalban,et al.  Role of B Cells in Multiple Sclerosis and Related Disorders , 2020, Annals of neurology.

[44]  D. Scott,et al.  Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression. , 2020, Cellular immunology.

[45]  Demin Zhou,et al.  In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells , 2020, Annals of the Rheumatic Diseases.

[46]  D. Scott,et al.  Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor. , 2020, Cellular immunology.

[47]  E. Radaelli,et al.  Antigen-specific B-cell depletion for precision therapy of mucosal pemphigus vulgaris. , 2020, The Journal of clinical investigation.

[48]  Weian Zhao,et al.  CAR-T design: Elements and their synergistic function , 2020, EBioMedicine.

[49]  Catherine C L Wong,et al.  Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy , 2020, Cell.

[50]  Linrong Lu,et al.  Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus , 2020, Cellular & Molecular Immunology.

[51]  C. King.  CAR NK Cell Therapy for T Follicular Helper Cells , 2020, Cell reports. Medicine.

[52]  Michael L. Wang,et al.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.

[53]  M. Khodoun,et al.  Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells , 2020, Cell reports. Medicine.

[54]  S. Sakaguchi,et al.  Regulatory T Cells and Human Disease. , 2020, Annual review of immunology.

[55]  T. Serwold,et al.  A biomimetic five-module chimeric antigen receptor (5MCAR) designed to target and eliminate antigen-specific T cells , 2020, Proceedings of the National Academy of Sciences.

[56]  A. Kamen,et al.  Adeno‐Associated Viral Vectors for Homology‐Directed Generation of CAR‐T Cells , 2020, Biotechnology journal.

[57]  A. Datta-Mannan,et al.  Monoclonal Antibodies: Past, Present and Future. , 2019, Handbook of experimental pharmacology.

[58]  T. Guo,et al.  A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial , 2019, Blood.

[59]  Rebecca L Yanovsky,et al.  Treatment of pemphigus vulgaris: part 2 – emerging therapies , 2019, Expert review of clinical immunology.

[60]  L. H. van den Berg,et al.  Multifocal motor neuropathy: controversies and priorities , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[61]  M. Manns,et al.  Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. , 2019, Journal of autoimmunity.

[62]  S. Jagannath,et al.  Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma , 2019, The New England journal of medicine.

[63]  M. Sadelain,et al.  CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape , 2019, Nature.

[64]  M. Radic,et al.  Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus , 2019, Science Translational Medicine.

[65]  J. Schachter,et al.  Early and late hematologic toxicity following CD19 CAR-T cells , 2019, Bone Marrow Transplantation.

[66]  Sean M. Hartig,et al.  Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes. , 2019, Journal of autoimmunity.

[67]  Hans Bitter,et al.  Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia , 2018, Nature Medicine.

[68]  N. Ding,et al.  Management of inflammatory bowel disease , 2018, The Medical journal of Australia.

[69]  M. Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[70]  Lin Yang,et al.  La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease. , 2018, Clinical immunology.

[71]  R. Geffers,et al.  Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC‐Specific Chimeric Antigen Receptor , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[72]  I. McInnes,et al.  Rheumatoid arthritis , 2016, The Lancet.

[73]  A. Lanzavecchia,et al.  Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease , 2016, Science.

[74]  M. Levings,et al.  Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. , 2016, The Journal of clinical investigation.

[75]  Lewis L. Lanier,et al.  NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.

[76]  M. Sadelain,et al.  Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.

[77]  Alexandria P. Cogdill,et al.  Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. , 2015, Cancer research.

[78]  S. Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[79]  S. Riddell,et al.  The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity , 2014, Cancer Immunology Research.

[80]  M. Essand,et al.  CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery , 2012, Journal of Neuroinflammation.

[81]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[82]  E. Elinav,et al.  Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. , 2009, Gastroenterology.

[83]  E. Elinav,et al.  Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. , 2008, Gastroenterology.

[84]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[85]  E. L. Prak,et al.  Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus , 2008, Annals of the rheumatic diseases.

[86]  M. Cottone,et al.  Maintenance infliximab for Crohn's disease , 2002, The Lancet.

[87]  Mark J. Smyth,et al.  Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-ζ vs FcεRI-γ1 , 2001, The Journal of Immunology.

[88]  M. Kiriakidou,et al.  Systemic Lupus Erythematosus , 1991, Annals of Internal Medicine.

[89]  P. Hwu,et al.  Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.

[90]  Nils E Gilhus.  Myasthenia Gravis. , 2016, The New England journal of medicine.